Home>About Us>Global Presence

Global Presence


Medreich started its business in the UK as a contract manufacturer in 1999. Over a period of time, Medreich developed and registered various dossiers in UK and has close to 130 licenses. These licenses are actively utilized to sell Medreich products in the UK, either in our own livery or in the livery of some of the key leading generic distributors in the market. Various products are under development and registration for Day 1 launch and Niche segments. We established a UK MHRA approved State of the Art Packing Lines and QC testing laboratory in Feltham, London along with Warehousing facility to cater the expanding demand of business in the European Region. The Business Development, Sales and Marketing, Regulatory & Logistics team based out of London work closely with the local and European customers.


Medreich Australia Pty Ltd is a company limited by shares that is incorporated and domiciled in Australia with its Head office in Sydney, Australia operational since 2006. Over 70 dossiers registered in TGA Australia and with Medsafe NZ. Currently supplying brands to 13 pharmaceutical partners across Australia and New Zealand. The principal activity of the company during the year was the importing and wholesaling of generic medicines. Importing OTC and Rx products manufactured in Medreich Ltd and supplying them to pharmaceutical companies in Australia (B to B)

Rich experience in handling controlled substance products. In house Regulatory, QA, Logistic, sales, marketing and NPD backed by teams in India. Can facilitate product development with R&D facility in Medreich India. The ongoing development of a strategic partnerships with key customers, a strong focus on customer service and the development of deeper customer portfolios has seen our business grow and we are now recognised as a key CDMO player in Australia and New Zealand. Our customer base is expanding and we have plans to further diversify our product portfolio which should see continued strong business growth. Medreich Australia is poised to significantly increase market share in CMO sector over the next 3 to 5 years.

To achieve our ambitious growth targets, we are focussed on the following critical success areas:

  • Developing strategic business partnerships
  • Growing the business with our current customers
  • Actively engaging new customers
  • Excellent customer service and on time supply
  • Expanding our portfolio

In the year 2007, Medreich entered into joint venture with Adcock Ingram, South Africa and established State of the Art - Manufacturing Facility in Bengaluru to Manufacture & Supply Solid dosage forms. This Joint Venture Company manufactures products for both the JV partners and other customers for various markets.

In the year 2023, it further expanded it’s Manufacturing Capacity by setting up a new State of the Art - Manufacturing Facility in Bengaluru, through it’s 100% Subsidiary Company - Adcock Ingram Pharma Private Limited to manufacture Tablets, Effervescent Granules & Tablets and other dosage forms.